In This Issue/Research Watch/News-in-Brief/News from the IASLC Tobacco Control Committee
Predicting Malignant Nodules from Screening CTs
Anti–PD-1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis
Transient Asymptomatic Pulmonary Opacities during Osimertinib Treatment: “Stop or Go” Decision
Slowing the Titanic: China's Epic Struggle with Tobacco
Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment
The IASLC Mesothelioma Staging Project: Improving Staging of a Rare Disease Through International Participation
The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma
The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma
The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma
Predicting Malignant Nodules from Screening CT Scans
Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma
Clinicopathological, Immunohistochemical, and Genetic Features of Primary Lung Adenocarcinoma Occurring in the Setting of Usual Interstitial Pneumonia Pattern
A 10-Gene Yin Yang Expression Ratio Signature for Stage IA and IB Non–Small Cell Lung Cancer
The Histologic Classifications of Lung Adenocarcinomas Are Discriminable by Unique Lineage Backgrounds
LincRNA-p21 Impacts Prognosis in Resected Non–Small Cell Lung Cancer Patients through Angiogenesis Regulation
IL-11 and CCL-1: Novel Protein Diagnostic Biomarkers of Lung Adenocarcinoma in Bronchoalveolar Lavage Fluid (BALF)
Overexpression of β-Catenin and Cyclin D1 is Associated with Poor Overall Survival in Patients with Stage IA–IIA Squamous Cell Lung Cancer Irrespective of Adjuvant Chemotherapy
Do New pN Subclassifications Proposed by IASLC's Lung Cancer Staging Project Agree with ypN Categories after Trimodality Therapy for Initial N2 Disease?
Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non–Small Cell Lung Cancer: A Phase I Dose Escalation Study
Postoperative Radiotherapy in Locally Invasive Malignancies of the Thymus: Patterns of Care and Survival
Neoadjuvant Chemotherapy versus Chemoradiation Prior to Esophagectomy: Impact on Rate of Complete Pathologic Response and Survival in Esophageal Cancer Patients
Anti-PD1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis
ALK Immunohistochemistry in NSCLC: Discordant Staining Can Impact Patient Treatment Regimen
An Anaplastic Lymphoma Kinase Immunohistochemistry–Negative but Fluorescence In Situ Hybridization–Positive Lung Adenocarcinoma Is Resistant to Crizotinib
Transient Asymptomatic Pulmonary Opacities Occurring during Osimertinib Treatment
Response to Pembrolizumab in a Patient with Relapsing Thymoma
Prophylactic Cranial Irradiation for Extensive-Stage Small Cell Lung Cancer
Prophylactic Cranial Irradiation for Extensive-Stage Small Cell Lung Cancer: Authors' Reply
Are All ALK Inhibitors Really Necessary?
Sequential Use of ALK Inhibitors: An Optional Approach